— Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected. — Total revenue remained flat at $5.60 billion, vs. $5.61 billion expected. Total product sales were flat at 5.5 billion. — Narrowed full year 2019 guidance on sales to $21.8-22.1 billion, from earlier esimtate of $21.6-22.1 billion. […]
“— Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected. — Total revenue remained flat at $5.60 billion, vs. $5.61 billion expected. Total product sales were flat at 5.5 billion. — Narrowed full year 2019 guidance on sales to $21.8-22.1 billion, from earlier esimtate of $21.6-22.1 billion. […]
· October 24, 2019
— Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected.
— Total revenue remained flat at $5.60 billion, vs. $5.61 billion expected. Total product sales were flat at 5.5 billion.
— Narrowed full year 2019 guidance on sales to $21.8-22.1 billion, from earlier esimtate of $21.6-22.1 billion.
— GILD shares have been trading sideways since the beginning of this year. The stock has so far declined 3% this year.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
